Nothing wrong with signing Distribution Deals. Whelan should be signing dozens of deals. Distributors never perform as promised but Whelan needs salespeople to try and sell her devices.
The only harm that came from the Synergy Deal was the way Whelan and Nalepka hyped that deal as a binding contract and a guarantee of revenue. Investors knew that was typical Whelan/Nalepka bullshit and the PPS barely moved -- it was sinking because quarterly revenues were dropping fast and that little piece of fiction didn't delay the sinking for long. The most egregious pumpers here pumped the Synergy Deal HARD but nobody bought. When the same pumpers tried to pump the NOPAIN Act, nobody bought. Now they're trying to pump the Electrome Deal, and while it has a better chance than Synergy or NOPAIN, nobody's buying.
The Electrome Deal might generate some revenues and it might never generate a single sale. Just another OTC game of Pitch 'n' Toss.
2025 revenues are going to SUCK. Luckily, nobody expects anything else from the Whelanator, so a bad Annual Filing won't matter in the slightest.
BIEL
Market Data 
Markets 
AI
